

Study Number: I10482B

Test Type: TOX

Route: Dosing in Feed

Species/Strain: Rat/Harlan Sprague Dawley

I04G: Mean Body Weight Gain

Test Compound: N-Butylbenzenesulfonamide

CAS Number: 3622-84-2

Date Report Requested: 03/10/2023

Time Report Requested: 14:32:47

Lab: Burleson Research Technologies

Study Number:

I10482B

Study Gender:

Both

PWG Approval Date:

See web page for date of PWG Approval

Version:

v1.4.3

Stat Version:

v2.9.1A

Study Number: I10482B

Test Type: TOX

Route: Dosing in Feed

Species/Strain: Rat/Harlan Sprague Dawley

I04G: Mean Body Weight Gain

Test Compound: N-Butylbenzenesulfonamide

CAS Number: 3622-84-2

Date Report Requested: 03/10/2023

Time Report Requested: 14:32:47

Lab: Burleson Research Technologies

F0 Females

Treatment Groups (ppm)

Phase	Days	0		250		500		1000	
		Wt Gain (g)	N	Wt Gain (g)	N	Wt Gain (g)	N	Wt Gain (g)	N
Gestation	3 - 6	12.4 ± 1.0 *	30	13.0 ± 1.2	29	15.4 ± 1.2	30	15.0 ± 1.0	29
	6 - 9	13.1 ± 0.8 **	30	11.5 ± 0.7	29	11.6 ± 0.6	30	10.1 ± 0.7 **	29
	9 - 12	13.1 ± 1.0	30	14.5 ± 0.7	29	13.5 ± 1.0	30	12.9 ± 0.7	29
	12 - 15	20.8 ± 1.0	30	18.6 ± 0.6	29	18.2 ± 0.9	30	18.2 ± 1.0	29
	15 - 18	41.1 ± 1.3 *	30	39.6 ± 1.2	29	38.0 ± 1.2	30	37.4 ± 1.3	29
	18 - 21	48.6 ± 1.4	30	46.2 ± 1.2	29	45.0 ± 1.4	30	46.1 ± 1.7	29
	6 - 21	136.8 ± 2.8 **	30	130.4 ± 2.3	29	126.3 ± 3.3 *	30	124.6 ± 3.4 **	29
Lactation	1 - 4	4.4 ± 1.2	30	6.7 ± 1.5	29	6.8 ± 1.5	30	5.7 ± 1.4	29
	4 - 7	10.6 ± 1.3	30	9.1 ± 1.3	29	7.5 ± 1.6	30	9.9 ± 1.3	29
	7 - 14	5.0 ± 2.4	30	6.8 ± 3.2	29	2.9 ± 2.1	30	7.5 ± 2.2	29
	14 - 21	-17.2 ± 2.6	30	-18.5 ± 3.1	29	-15.3 ± 2.5	30	-20.1 ± 2.8	29
	21 - 28	-4.8 ± 2.6	30	-6.5 ± 3.2	29	-5.7 ± 2.3	30	-1.1 ± 3.2	29
	1 - 28	-2.0 ± 1.6	30	-2.5 ± 1.9	29	-3.9 ± 1.8	30	1.9 ± 1.5	29

Study Number: I10482B

Test Type: TOX

Route: Dosing in Feed

Species/Strain: Rat/Harlan Sprague Dawley

I04G: Mean Body Weight Gain

Test Compound: N-Butylbenzenesulfonamide

CAS Number: 3622-84-2

Date Report Requested: 03/10/2023

Time Report Requested: 14:32:47

Lab: Burleson Research Technologies

F1 Males: SRBC

Phase	Days	Treatment Groups (ppm)							
		0		250		500		1000	
		Wt Gain (g)	N	Wt Gain (g)	N	Wt Gain (g)	N	Wt Gain (g)	N
SD	0 - 7	43.6 ± 1.0 **	12	44.0 ± 1.3	12	39.8 ± 1.0 *	12	39.1 ± 0.8 **	12
	7 - 14	48.4 ± 1.1 **	12	51.4 ± 0.8	12	45.3 ± 1.2 *	12	43.1 ± 1.2 **	12
	14 - 21	45.1 ± 1.5 **	12	41.8 ± 1.1 *	12	40.9 ± 1.0 *	12	38.2 ± 1.0 **	12
	21 - 28	42.3 ± 1.1 **	12	41.5 ± 1.5	12	38.2 ± 1.1 *	12	37.8 ± 0.9 **	12
	28 - 35	27.8 ± 1.4 **	12	27.3 ± 1.7	12	23.6 ± 1.6	12	21.9 ± 1.7 *	12
	35 - 42	23.9 ± 1.4	12	24.9 ± 2.3	12	21.6 ± 2.1	12	20.0 ± 1.9	12
	42 - 49	9.8 ± 1.2	12	10.3 ± 1.7	12	9.3 ± 1.9	12	8.0 ± 1.6	12

Study Number: I10482B

Test Type: TOX

Route: Dosing in Feed

Species/Strain: Rat/Harlan Sprague Dawley

I04G: Mean Body Weight Gain

Test Compound: N-Butylbenzenesulfonamide

CAS Number: 3622-84-2

Date Report Requested: 03/10/2023

Time Report Requested: 14:32:47

Lab: Burleson Research Technologies

F1 Females: SRBC

Phase	Days	Treatment Groups (ppm)							
		0		250		500		1000	
		Wt Gain (g)	N	Wt Gain (g)	N	Wt Gain (g)	N	Wt Gain (g)	N
SD	0 - 7	31.0 ± 1.1 *	12	31.0 ± 1.0	12	28.9 ± 0.8	12	28.8 ± 0.9	12
	7 - 14	26.3 ± 1.0	12	28.7 ± 1.5	12	24.7 ± 1.3	12	25.6 ± 1.1	11
	14 - 21	21.2 ± 3.1	12	18.8 ± 3.0	12	17.8 ± 1.5	12	18.9 ± 4.3	11
	21 - 28	15.6 ± 4.7	12	17.3 ± 3.6	12	18.1 ± 2.1	12	15.9 ± 4.8	11
	28 - 35	15.8 ± 1.4 *	12	16.4 ± 2.3	12	9.7 ± 1.2 *	12	11.4 ± 1.2	11
	35 - 42	13.3 ± 0.8	12	9.1 ± 2.2	12	10.8 ± 1.8	12	13.4 ± 1.2	11
	42 - 49	6.3 ± 1.3	12	4.6 ± 0.8	12	6.6 ± 1.1	12	4.4 ± 1.1	11

Study Number: I10482B

Test Type: TOX

Route: Dosing in Feed

Species/Strain: Rat/Harlan Sprague Dawley

I04G: Mean Body Weight Gain

Test Compound: N-Butylbenzenesulfonamide

CAS Number: 3622-84-2

Date Report Requested: 03/10/2023

Time Report Requested: 14:32:47

Lab: Burlinson Research Technologies

F1 Males: KLH

Treatment Groups (ppm)

Phase	Days	0		250		500		1000		15 mg/kg CPS	
		Wt Gain (g)	N	Wt Gain (g)	N	Wt Gain (g)	N	Wt Gain (g)	N	Wt Gain (g)	N
SD	0 - 7	43.9 ± 0.8 *	12	40.4 ± 0.9	12	39.4 ± 1.2 **	12	40.3 ± 1.1 *	12	NA	
	7 - 14	47.0 ± 1.4 **	12	46.7 ± 1.1	12	42.8 ± 1.0 *	12	42.1 ± 1.0 **	12	NA	
	14 - 21	44.9 ± 0.9 **	12	43.2 ± 1.8	12	39.3 ± 0.9 **	12	40.4 ± 0.8 **	12	NA	
	21 - 28	40.5 ± 1.3	12	39.6 ± 1.5	12	38.7 ± 1.3	12	37.1 ± 0.8	12	NA	
	28 - 35	37.3 ± 1.4 **	12	36.8 ± 1.1	12	31.1 ± 1.2 **	12	32.9 ± 1.4 **	12	NA	
	35 - 42	25.2 ± 1.1	12	23.3 ± 1.8	12	23.4 ± 0.9	12	23.8 ± 1.3	12	NA	
	42 - 49	22.2 ± 0.9 *	12	18.8 ± 0.9	12	19.3 ± 1.8	12	18.2 ± 1.6	12	19.1 ± 4.3	8
	49 - 56	18.2 ± 2.1 *	12	17.6 ± 1.2	12	11.4 ± 1.1 **	12	14.3 ± 0.9	12	12.8 ± 3.3	8
	56 - 63	9.4 ± 1.1	12	11.3 ± 0.9	12	12.1 ± 0.9	12	9.7 ± 1.1	12	-13.8 ± 0.7 **	8
	63 - 70	11.5 ± 1.1	12	8.0 ± 1.0 *	12	8.8 ± 0.8	12	10.8 ± 0.6	12	-14.5 ± 5.1 **	8

Study Number: I10482B

Test Type: TOX

Route: Dosing in Feed

Species/Strain: Rat/Harlan Sprague Dawley

I04G: Mean Body Weight Gain

Test Compound: N-Butylbenzenesulfonamide

CAS Number: 3622-84-2

Date Report Requested: 03/10/2023

Time Report Requested: 14:32:47

Lab: Burleson Research Technologies

F1 Females: KLH

Treatment Groups (ppm)

Phase	Days	0		250		500		1000		15 mg/kg CPS	
		Wt Gain (g)	N	Wt Gain (g)	N	Wt Gain (g)	N	Wt Gain (g)	N	Wt Gain (g)	N
SD	0 - 7	30.3 ± 1.2	12	27.9 ± 0.8	12	29.2 ± 1.1	12	29.0 ± 0.9	12	NA	
	7 - 14	26.2 ± 0.8	12	28.6 ± 1.5	12	27.3 ± 1.2	12	27.8 ± 0.8	12	NA	
	14 - 21	18.2 ± 1.1	12	21.3 ± 1.4	12	18.3 ± 1.0	12	17.8 ± 0.8	12	NA	
	21 - 28	17.6 ± 0.9	12	17.5 ± 1.8	12	18.1 ± 0.9	12	16.1 ± 0.7	12	NA	
	28 - 35	17.0 ± 1.3	12	15.4 ± 0.6	12	15.4 ± 0.7	12	14.5 ± 1.2	12	NA	
	35 - 42	10.6 ± 0.7	12	10.2 ± 1.0	12	10.8 ± 0.9	12	11.6 ± 1.0	12	NA	
	42 - 49	10.2 ± 1.2	12	9.1 ± 0.9	12	9.7 ± 1.5	12	6.9 ± 1.4	12	12.3 ± 2.4	8
	49 - 56	5.8 ± 1.3	12	5.6 ± 1.2	12	6.3 ± 1.1	12	6.3 ± 1.0	12	3.6 ± 2.7	8
	56 - 63	4.0 ± 1.2	12	3.9 ± 0.8	12	3.6 ± 1.0	12	6.8 ± 1.0	12	-5.1 ± 1.6 **	8

Study Number: I10482B

Test Type: TOX

Route: Dosing in Feed

Species/Strain: Rat/Harlan Sprague Dawley

I04G: Mean Body Weight Gain

Test Compound: N-Butylbenzenesulfonamide

CAS Number: 3622-84-2

Date Report Requested: 03/10/2023

Time Report Requested: 14:32:47

Lab: Burleson Research Technologies

F1 Males: Immunophenotyping

Phase	Days	Treatment Groups (ppm)									
		0		250		500		1000		15 mg/kg CPS	
		Wt Gain (g)	N	Wt Gain (g)	N	Wt Gain (g)	N	Wt Gain (g)	N	Wt Gain (g)	N
SD	0 - 7	43.3 ± 0.8	12	41.1 ± 1.3	12	40.2 ± 1.0	12	40.9 ± 0.8	12	NA	
	7 - 14	45.5 ± 1.6 *	12	45.8 ± 1.0	12	43.1 ± 1.2	12	42.6 ± 0.9	12	NA	
	14 - 21	43.8 ± 0.8	12	43.5 ± 1.3	12	39.7 ± 1.6	11	43.7 ± 1.1	12	NA	
	21 - 28	41.4 ± 1.1 *	12	39.6 ± 1.3	12	36.8 ± 1.3 *	11	37.5 ± 1.2	12	NA	
	28 - 35	34.3 ± 1.2 *	12	35.2 ± 1.0	12	31.1 ± 1.7	11	30.5 ± 1.4	11	NA	
	35 - 42	25.3 ± 1.0	12	24.1 ± 1.2	12	22.7 ± 2.2	11	24.3 ± 1.5	11	NA	
	42 - 49	19.5 ± 1.0	12	21.3 ± 1.6	12	16.1 ± 0.9	11	17.3 ± 1.2	12	24.5 ± 2.4	8
	49 - 56	14.4 ± 3.0	12	15.1 ± 1.2	12	19.1 ± 1.7	11	14.9 ± 1.0	12	16.6 ± 2.4	8

Study Number: I10482B

Test Type: TOX

Route: Dosing in Feed

Species/Strain: Rat/Harlan Sprague Dawley

I04G: Mean Body Weight Gain

Test Compound: N-Butylbenzenesulfonamide

CAS Number: 3622-84-2

Date Report Requested: 03/10/2023

Time Report Requested: 14:32:47

Lab: Burleson Research Technologies

F1 Females: Immunophenotyping

Phase	Days	Treatment Groups (ppm)									
		0		250		500		1000		15 mg/kg CPS	
		Wt Gain (g)	N	Wt Gain (g)	N	Wt Gain (g)	N	Wt Gain (g)	N	Wt Gain (g)	N
SD	0 - 7	32.0 ± 0.8 **	12	29.1 ± 0.6	12	30.0 ± 1.2	12	27.2 ± 0.7 **	12	NA	
	7 - 14	28.4 ± 0.8	12	28.7 ± 0.9	12	29.3 ± 0.8	12	28.3 ± 0.6	12	NA	
	14 - 21	19.1 ± 0.9	12	20.5 ± 1.1	12	17.3 ± 1.2	12	20.0 ± 0.9	12	NA	
	21 - 28	17.6 ± 1.7	12	18.3 ± 1.2	12	18.4 ± 0.6	12	15.4 ± 0.8	12	NA	
	28 - 35	17.1 ± 2.0	12	16.2 ± 1.9	12	15.4 ± 1.2	12	13.1 ± 1.2	12	NA	
	35 - 42	11.1 ± 1.2	12	11.9 ± 1.4	12	13.2 ± 1.5	12	12.2 ± 1.1	12	NA	
	42 - 49	8.3 ± 1.5	12	10.4 ± 1.1	12	7.3 ± 1.8	12	8.7 ± 0.9	12	8.9 ± 2.4	8

Study Number: I10482B

Test Type: TOX

Route: Dosing in Feed

Species/Strain: Rat/Harlan Sprague Dawley

I04G: Mean Body Weight Gain

Test Compound: N-Butylbenzenesulfonamide

CAS Number: 3622-84-2

Date Report Requested: 03/10/2023

Time Report Requested: 14:32:47

Lab: Burleson Research Technologies

F1 Males: CTL

Phase	Days	Treatment Groups (ppm)							
		0		250		500		1000	
		Wt Gain (g)	N	Wt Gain (g)	N	Wt Gain (g)	N	Wt Gain (g)	N
SD	0 - 7	43.1 ± 1.0	12	42.4 ± 1.3	11	42.2 ± 1.1	12	40.5 ± 0.9	12
	7 - 14	49.4 ± 1.4 **	12	49.3 ± 0.7	11	46.0 ± 0.7 *	12	45.6 ± 1.0 **	12
	14 - 21	44.8 ± 1.0 **	12	41.8 ± 0.9 *	11	40.8 ± 0.7 **	12	39.5 ± 1.2 **	12
	21 - 28	43.8 ± 1.3	12	39.6 ± 1.0	11	34.4 ± 5.5	12	40.5 ± 1.1	12
	28 - 35	28.6 ± 1.4	12	26.9 ± 2.8	11	33.7 ± 5.7	12	25.3 ± 2.0	12
	35 - 42	25.3 ± 2.2	12	17.9 ± 2.4 *	11	20.4 ± 1.8	12	27.8 ± 1.8	12
	42 - 49	4.2 ± 1.2	12	1.6 ± 1.5	11	9.3 ± 2.0	12	2.6 ± 3.5	12
	49 - 56	10.8 ± 2.8	12	14.1 ± 2.1	11	16.3 ± 1.8	12	12.1 ± 3.4	12

Study Number: I10482B

Test Type: TOX

Route: Dosing in Feed

Species/Strain: Rat/Harlan Sprague Dawley

I04G: Mean Body Weight Gain

Test Compound: N-Butylbenzenesulfonamide

CAS Number: 3622-84-2

Date Report Requested: 03/10/2023

Time Report Requested: 14:32:47

Lab: Burleson Research Technologies

F1 Females: CTL

Phase	Days	Treatment Groups (ppm)							
		0		250		500		1000	
		Wt Gain (g)	N	Wt Gain (g)	N	Wt Gain (g)	N	Wt Gain (g)	N
SD	0 - 7	33.1 ± 0.9	12	30.1 ± 0.6 *	12	30.1 ± 0.7 *	12	30.5 ± 0.6 *	12
	7 - 14	27.8 ± 0.8	12	27.8 ± 0.6	12	25.3 ± 1.3	12	25.8 ± 1.3	12
	14 - 21	19.3 ± 2.8	12	17.6 ± 2.7	12	18.7 ± 1.4	12	18.1 ± 4.1	12
	21 - 28	18.4 ± 3.2	12	17.1 ± 3.1	12	16.9 ± 1.4	12	18.8 ± 5.0	12
	28 - 35	13.4 ± 1.4 *	12	14.3 ± 1.3	12	11.9 ± 1.7	12	8.3 ± 1.5 *	12
	35 - 42	9.9 ± 1.3	12	9.5 ± 1.1	12	11.1 ± 0.9	12	12.8 ± 1.5	12
	42 - 49	-0.5 ± 1.3	12	-0.8 ± 2.0	12	2.6 ± 1.1	12	-1.1 ± 1.2	12

Study Number: I10482B

Test Type: TOX

Route: Dosing in Feed

Species/Strain: Rat/Harlan Sprague Dawley

I04G: Mean Body Weight Gain

Test Compound: N-Butylbenzenesulfonamide

CAS Number: 3622-84-2

Date Report Requested: 03/10/2023

Time Report Requested: 14:32:47

Lab: Burleson Research Technologies

F1 Males: Immunopathology

Phase	Days	Treatment Groups (ppm)									
		0		250		500		1000		15 mg/kg CPS	
		Wt Gain (g)	N	Wt Gain (g)	N	Wt Gain (g)	N	Wt Gain (g)	N	Wt Gain (g)	N
SD	0 - 7	43.7 ± 0.9 **	12	40.1 ± 0.8 *	11	39.9 ± 1.0 **	12	39.6 ± 1.0 **	12	NA	
	7 - 14	48.4 ± 1.3 **	12	45.7 ± 1.1	11	43.4 ± 1.4 **	12	41.8 ± 0.8 **	12	NA	
	14 - 21	44.2 ± 1.6	12	44.4 ± 1.6	11	39.3 ± 1.2	12	41.8 ± 1.5	12	NA	
	21 - 28	42.0 ± 2.0 *	12	38.5 ± 1.7	11	36.8 ± 1.6	12	37.7 ± 0.9	12	NA	
	28 - 35	35.7 ± 1.1	12	33.0 ± 1.8	11	30.9 ± 1.5	12	33.5 ± 1.4	11	NA	
	35 - 42	24.8 ± 1.9	12	23.1 ± 1.6	11	22.9 ± 1.7	12	20.5 ± 2.7	11	NA	
	42 - 49	20.3 ± 1.7	12	18.5 ± 1.4	11	19.1 ± 1.7	12	18.8 ± 2.0	12	22.3 ± 1.7	8
	49 - 56	14.3 ± 4.1	12	14.2 ± 6.2	11	16.1 ± 7.7	12	16.6 ± 6.2	12	4.0 ± 2.6 *	8

Study Number: I10482B

Test Type: TOX

Route: Dosing in Feed

Species/Strain: Rat/Harlan Sprague Dawley

I04G: Mean Body Weight Gain

Test Compound: N-Butylbenzenesulfonamide

CAS Number: 3622-84-2

Date Report Requested: 03/10/2023

Time Report Requested: 14:32:47

Lab: Burleson Research Technologies

F1 Females: Immunopathology

Phase	Days	Treatment Groups (ppm)									
		0		250		500		1000		15 mg/kg CPS	
		Wt Gain (g)	N	Wt Gain (g)	N	Wt Gain (g)	N	Wt Gain (g)	N	Wt Gain (g)	N
SD	0 - 7	30.8 ± 1.4	12	30.4 ± 0.7	12	29.8 ± 1.5	12	27.9 ± 1.1	12	NA	
	7 - 14	28.3 ± 1.2	12	28.3 ± 1.1	12	28.5 ± 1.1	12	28.3 ± 1.3	12	NA	
	14 - 21	17.7 ± 1.0	12	19.0 ± 1.0	12	18.4 ± 0.8	12	19.1 ± 0.8	12	NA	
	21 - 28	16.1 ± 1.5	12	16.0 ± 1.3	12	16.4 ± 0.7	12	16.1 ± 0.8	12	NA	
	28 - 35	16.4 ± 2.2	12	16.2 ± 1.2	12	13.8 ± 0.9	12	15.4 ± 1.1	12	NA	
	35 - 42	12.0 ± 1.1	12	10.7 ± 1.4	12	13.3 ± 1.1	12	12.4 ± 1.0	12	NA	
	42 - 49	8.9 ± 1.8	12	9.0 ± 1.1	12	9.3 ± 0.9	12	8.5 ± 1.0	12	3.0 ± 2.1 *	8

Study Number: I10482B

Test Type: TOX

Route: Dosing in Feed

Species/Strain: Rat/Harlan Sprague Dawley

I04G: Mean Body Weight Gain

Test Compound: N-Butylbenzenesulfonamide

CAS Number: 3622-84-2

Date Report Requested: 03/10/2023

Time Report Requested: 14:32:47

Lab: Burleson Research Technologies

LEGEND

Data are displayed as mean \pm SEM

GD - Gestation Day; LD - Lactation Day; SD - Study Day

Statistical analysis of weight data performed by Jonckheere (trend) and Williams or Dunnett (pairwise) tests.

Statistical analysis for the positive control group compared to the vehicle control group was performed using the t-Test.

Statistical significance for the control group indicates a significant trend test

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group

* Statistically significant at $P \leq 0.05$

** Statistically significant at $P \leq 0.01$

CPS = Cyclophosphamide

NA - Not Available

**** END OF REPORT ****